Form 4: Ligand Pharma Director Sells Shares Under 10b5-1 Plan

A director at Ligand Pharmaceuticals Inc. sold 467 shares of common stock on September 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• John W. Kozarich, a Director of Ligand Pharmaceuticals Inc. (LGND), reported the sale of 467 shares of common stock.
• The transactions occurred on September 2, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2025.
• The sales were conducted in three separate transactions at weighted-average prices of $161.5135, $162.5188, and $164.248.
• Following these transactions, Mr. Kozarich directly beneficially owns 45,522 shares of Ligand Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sale of shares by a director is a routine disclosure for a Form 4. The fact that it was executed under a Rule 10b5-1 plan suggests it was pre-scheduled and not indicative of a change in sentiment regarding the company's prospects. The number of shares sold is also relatively small compared to the director's remaining holdings, leading to a neutral sentiment.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled sales and reducing the perception of opportunistic trading based on non-public information.

Negatives

• The sale represents a reduction in direct insider ownership, although the amount is relatively small compared to the director's remaining holdings.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider trading report is specific to Ligand Pharmaceuticals Inc. and does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is small and pre-planned, not signaling a change in company fundamentals.

Key Dates

Recommendation

The director's sale of a relatively small number of shares under a pre-arranged 10b5-1 plan is a routine event and does not signal a change in the company's fundamental outlook or warrant a change in investment thesis. Investors should continue to hold based on broader company performance and market conditions.

Keywords

Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Equity Transaction